BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang P, Xu B, Gui L, Wang W, Xiu M, Zhang X, Sun G, Zhu X, Zou J. A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. Biomark Res 2021;9:24. [PMID: 33845905 DOI: 10.1186/s40364-021-00271-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Meng Y, Wang B, Wang L, Cao J, Tao Z, Li T, Yao W, Hu X. Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study. Front Oncol 2022;12:775081. [DOI: 10.3389/fonc.2022.775081] [Reference Citation Analysis]
2 Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, Sun T, Teng Y, Wu X, Ouyang Q, Yan X, Cheng J, Liu Q, Feng J, Wang X, Yin Y, Shi Y, Pan Y, Wang Y, Xie W, Yan M, Liu Y, Yan P, Wu F, Zhu X, Zou J; DAWNA-1 Study Consortium. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med 2021;27:1904-9. [PMID: 34737452 DOI: 10.1038/s41591-021-01562-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 . Dalpiciclib Extends Progression-Free Survival in HR+/HER2- Advanced Breast Cancer. Oncologist 2021;26 Suppl 3:S9-S10. [PMID: 34152061 DOI: 10.1002/onco.13865] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Mezni E, Sabatier R, Goncalves A, Vicier C. [Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021]. Bull Cancer 2022:S0007-4551(22)00001-7. [PMID: 35115114 DOI: 10.1016/j.bulcan.2021.12.009] [Reference Citation Analysis]